In this study, 35 participants were randomly allocated to a lixisenatide (20 mg) group or once-daily insulin glulisine treatment group
Long wait times, uncomfortable waiting rooms, and a lack of specialized knowledge in metabolic health can make the process frustrating
Practice Areas Partner Ron Parry Ron Parry is a seasoned trial attorney with decades of litigation experience representing clients in high-stakes class actions, complex commercial disputes, and personal injury matters
#CardiovascularDrugs #Cardiology #HeartHealth #PharmaceuticalIndustry #CardiovascularDisease #PharmaInnovation To view or add a comment, sign in : : The biosimilars market is expected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period
Ageing Res Rev 89: 101979
The 5% Problem: The Access Gap Behind GLP-1s, Hormone Therapy, and Midlife Weight Gain What the science actually shows about menopause, metabolism, and GLP-1s - and why the biggest barrier isnt biology, but access to evidence-based care
